[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 6,937 common shares held by an insider through Morgan Stanley Smith Barney LLC, with an aggregate market value of $611,644.31 based on the filing. The shares represent a small portion of the company's outstanding common stock (21,688,772 shares outstanding) and the proposed sale is slated to occur on 08/18/2025 on NASDAQ.
The filing also lists the acquisition history for the shares being offered: 2,527 restricted shares acquired on 08/21/2024 and 4,410 restricted shares acquired on 05/21/2025, both issued by the company. No securities were reported sold by the person in the prior three months on this form, and the filer certifies that they have no undisclosed material adverse information.
- Regulatory compliance: The filer submitted a complete Rule 144 notice including broker, share count, market value, and acquisition history
- Transparency: Acquisition dates and number of restricted shares are disclosed, enabling clear tracing of grant origins
- Insider sale: An affiliate intends to sell 6,937 shares valued at $611,644.31, which is a disposition of insider-held equity
Insights
TL;DR: Routine Rule 144 disclosure of insider sale; documentation aligns with restricted-stock vesting and brokerage placement.
The filing provides the required Rule 144 notice for a proposed sale of 6,937 shares through Morgan Stanley Smith Barney, documenting acquisition dates and that the shares were issued as restricted stock by the issuer. From a compliance perspective, the form contains the essential elements: broker details, number of shares, market value, outstanding shares, acquisition dates, and a certification regarding material nonpublic information. There are no reports of prior sales in the past three months, which simplifies aggregation questions under Rule 144(e).
TL;DR: Insider sale size is immaterial to capitalization; transaction appears administrative rather than market-moving.
The proposed sale equals roughly 0.032% of the reported outstanding common shares, indicating the transaction is unlikely to materially affect market supply or the company’s capitalization. The shares originated from restricted-stock issuances on two dates in 2024 and 2025, consistent with vesting/compensation events. The disclosure is standard for officer/affiliate liquidity events and contains no additional market-impacting details such as planned block trades or large-volume arrangements.